ThinkSabio

$GMAB

$53.15▲ -3.6% YTD

13 SEC 13D/G filings tracked · Last updated Nov 5, 2026

Filing History
News
GMAB ▼ -3.6% - Genmab A/S
CP $53.15▲ -3.6%Nov 5, 2026 · ThinkSabio Blog

$GMAB reported Q3 2026 EPS of $5.51, beating the $0.33 estimate by 1569.7%. Revenue of $1.2B missed the $6.7B estimate by 82.2%…

News
GMAB ▲ +0.8% - Genmab A/S
CP $55.95▲ +0.8%Nov 4, 2026 · ThinkSabio Blog

$GMAB Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 Ameri…

News
GMAB ▲ +34.1% - Genmab A/S
CP $59.92▲ +34.1%Oct 28, 2026 · ThinkSabio Blog

$GMAB highs…

News
GMAB ▲ +25.5% - Genmab A/S
CP $56.05▲ +25.5%Oct 28, 2026 · ThinkSabio Blog

$GMAB new highs…

News
GMAB ▲ +19.6% - Genmab A/S
CP $53.43▲ +19.6%Oct 28, 2026 · ThinkSabio Blog

$GMAB new highs…

News
GMAB ▲ +16.1% - Genmab A/S
CP $51.87▲ +16.1%Oct 28, 2026 · ThinkSabio Blog

$GMAB new highs…

News
GMAB ▲ +16.1% - Genmab A/S
CP $51.87▲ +16.1%Oct 28, 2026 · ThinkSabio Blog

$GMAB Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combi…

News
GMAB ▲ +3.5% - Genmab A/S
CP $45.31▲ +3.5%Oct 26, 2026 · ThinkSabio Blog

$GMAB Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Lin…

News
GMAB ▲ +7.6% - Genmab A/S
CP $43.05▲ +7.6%Oct 23, 2026 · ThinkSabio Blog

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Surv…

News
GMAB ▼ -1.5% - Genmab A/S
CP $37.23▲ -1.5%Oct 7, 2026 · ThinkSabio Blog

$GMAB H.C. Wainwright raised the firm's price target on Genmab to $50 from $40 and keeps a Buy rating on the shares. The company announced positive re…

News
GMAB ▼ -1.5% - Genmab A/S
CP $37.23▲ -1.5%Oct 7, 2026 · ThinkSabio Blog

$GMAB Guggenheim analyst Michael Schmidt raised the firm's price target on Genmab to $58 from $54 and keeps a Buy rating on the shares, which remain a…

SEC 13D/G
GMAB - Genmab A/S - SEC Filing Update (05-OCT-2026) | ThinkSabio - Stocks Simplified
$38.80▲ 21.90%Oct 6, 2026 · ThinkSabio Blog

$GMAB SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #GMAB Genmab A/S : $38.80 Sector: Healthcare | YTD: 🔼+ 21.90% Th…

News
GMAB ▲ +11.0% - Genmab A/S
CP $38.59▲ +11.0%Oct 5, 2026 · ThinkSabio Blog

$GMAB Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Surviva…